• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

病例报告:全外显子测序联合多重连接探针扩增技术揭示了一名患有脊髓性肌萎缩症和杜氏肌营养不良症联合表现患者的两个基因中的变异。

Case Report: Whole-Exome Sequencing With MLPA Revealed Variants in Two Genes in a Patient With Combined Manifestations of Spinal Muscular Atrophy and Duchenne Muscular Dystrophy.

作者信息

Xia Yu, Feng Yijie, Xu Lu, Chen Xiaoyang, Gao Feng, Mao Shanshan

机构信息

National Clinical Research Center for Child Health, Department of Neurology, The Children's Hospital, Zhejiang University School of Medicine, Hangzhou, China.

National Clinical Research Center for Child Health, Department of Developmental and Behavioral Pediatrics, The Children's Hospital, Zhejiang University School of Medicine, Hangzhou, China.

出版信息

Front Genet. 2021 Mar 10;12:605611. doi: 10.3389/fgene.2021.605611. eCollection 2021.

DOI:10.3389/fgene.2021.605611
PMID:33777091
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7987946/
Abstract

Spinal muscular atrophy (SMA) and Duchenne muscular dystrophy (DMD) are two common kinds of neuromuscular disorders sharing various similarities in clinical manifestations. SMA is an autosomal recessive genetic disorder that results from biallelic mutations of the survival motor neuron 1 gene (; OMIM 600354) on the 5q13 chromosome. DMD is an X-linked disorder caused by defects in the gene (OMIM 300377) on the X chromosome. Here, for the first time, we report a case from a Chinese family who present with clinical manifestations of both two diseases, including poor motor development and progressive muscle weakness. We identified a homozygous deletion in exons 7 and 8 of the gene and a deletion in exon 50 of the gene by whole-exome sequencing (WES) and multiplex ligation-dependent probe amplification (MLPA). This case expands our understanding of diagnosis for synchronous SMA and DMD and highlights the importance of various genetic testing methods, including WES, in differential diagnosis of neuromuscular diseases.

摘要

脊髓性肌萎缩症(SMA)和杜氏肌营养不良症(DMD)是两种常见的神经肌肉疾病,在临床表现上有诸多相似之处。SMA是一种常染色体隐性遗传病,由5号染色体长臂13区(5q13)上的生存运动神经元1基因(;OMIM 600354)双等位基因突变引起。DMD是一种X连锁疾病,由X染色体上的基因(OMIM 300377)缺陷导致。在此,我们首次报告了一个来自中国家庭的病例,该病例同时具有这两种疾病的临床表现,包括运动发育迟缓及进行性肌无力。通过全外显子组测序(WES)和多重连接依赖探针扩增技术(MLPA),我们在基因的第7和第8外显子中发现了一个纯合缺失,在基因的第50外显子中发现了一个缺失。该病例拓宽了我们对同步发生的SMA和DMD诊断的认识,并突出了包括WES在内的各种基因检测方法在神经肌肉疾病鉴别诊断中的重要性。

相似文献

1
Case Report: Whole-Exome Sequencing With MLPA Revealed Variants in Two Genes in a Patient With Combined Manifestations of Spinal Muscular Atrophy and Duchenne Muscular Dystrophy.病例报告:全外显子测序联合多重连接探针扩增技术揭示了一名患有脊髓性肌萎缩症和杜氏肌营养不良症联合表现患者的两个基因中的变异。
Front Genet. 2021 Mar 10;12:605611. doi: 10.3389/fgene.2021.605611. eCollection 2021.
2
Application of a Multiplex Ligation-Dependent Probe Amplification-Based Next-Generation Sequencing Approach for the Detection of Pathogenesis of Duchenne Muscular Dystrophy and Spinal Muscular Atrophy Caused by Copy Number Aberrations.基于多重连接依赖探针扩增的下一代测序技术在检测 Duchenne 肌营养不良症和由拷贝数异常引起的脊髓性肌萎缩症的发病机制中的应用。
Mol Neurobiol. 2024 Jan;61(1):200-211. doi: 10.1007/s12035-023-03572-9. Epub 2023 Aug 19.
3
Corrigendum: Case Report: Whole-Exome Sequencing With MLPA Revealed Variants in Two Genes in a Patient With Combined Manifestations of Spinal Muscular Atrophy and Duchenne Muscular Dystrophy.勘误:病例报告:采用多重连接依赖探针扩增技术的全外显子组测序揭示了一名患有脊髓性肌萎缩症和杜氏肌营养不良症联合表现患者两个基因中的变异。
Front Genet. 2021 Jun 1;12:684042. doi: 10.3389/fgene.2021.684042. eCollection 2021.
4
Overview of gene therapy in spinal muscular atrophy and Duchenne muscular dystrophy.脊髓性肌萎缩症和杜氏肌营养不良症的基因治疗概述。
Pediatr Pulmonol. 2021 Apr;56(4):710-720. doi: 10.1002/ppul.25055. Epub 2020 Sep 14.
5
Current and emerging therapies for Duchenne muscular dystrophy and spinal muscular atrophy.杜氏肌营养不良症和脊髓性肌萎缩症的现有和新兴疗法。
Pharmacol Ther. 2021 Apr;220:107719. doi: 10.1016/j.pharmthera.2020.107719. Epub 2020 Oct 29.
6
Mutation analysis of 419 family and prenatal diagnosis of 339 cases of spinal muscular atrophy in China.在中国,对 419 个家系进行突变分析及对 339 例脊髓性肌萎缩症进行产前诊断。
BMC Med Genet. 2020 Jun 18;21(1):133. doi: 10.1186/s12881-020-01069-z.
7
Genetic analysis of 62 Chinese families with Duchenne muscular dystrophy and strategies of prenatal diagnosis in a single center.62 个中国杜氏肌营养不良症家系的遗传学分析及单中心产前诊断策略。
BMC Med Genet. 2019 Nov 14;20(1):180. doi: 10.1186/s12881-019-0912-x.
8
A resolved discrepancy between multiplex PCR and multiplex ligation-dependent probe amplification by targeted next-generation sequencing discloses a novel partial exonic deletion in the Duchenne muscular dystrophy gene.多重PCR与多重连接依赖探针扩增通过靶向新一代测序产生的一个已解决的差异揭示了杜氏肌营养不良症基因中的一种新型部分外显子缺失。
J Clin Lab Anal. 2018 Oct;32(8):e22575. doi: 10.1002/jcla.22575. Epub 2018 May 25.
9
Gene therapy for selected neuromuscular and trinucleotide repeat disorders - An insight to subsume South Asia for multicenter clinical trials.针对特定神经肌肉疾病和三核苷酸重复序列疾病的基因治疗——将南亚纳入多中心临床试验的见解。
IBRO Neurosci Rep. 2023 Jan 30;14:146-153. doi: 10.1016/j.ibneur.2023.01.009. eCollection 2023 Jun.
10
Genetic Analysis of Forty MLPA-Negative Duchenne Muscular Dystrophy Patients by Whole-Exome Sequencing.全外显子组测序分析四十例 MLPA 阴性杜氏肌营养不良症患者的基因突变。
J Mol Neurosci. 2022 May;72(5):1098-1107. doi: 10.1007/s12031-022-01980-5. Epub 2022 Feb 26.

引用本文的文献

1
Next generation sequencing panel as an effective approach to genetic testing in patients with a highly variable phenotype of neuromuscular disorders.下一代测序 panel 作为一种有效的遗传检测方法,适用于具有高度可变表型的神经肌肉疾病患者。
Neurogenetics. 2024 Jul;25(3):233-247. doi: 10.1007/s10048-024-00762-y. Epub 2024 May 17.
2
Duchenne muscular dystrophy caused by a deletion (c.5021del) in exon 35 of the DMD gene: A case report and review of the literature.由DMD基因第35外显子缺失(c.5021del)引起的杜氏肌营养不良症:一例报告及文献复习
Heliyon. 2024 Mar 27;10(7):e28677. doi: 10.1016/j.heliyon.2024.e28677. eCollection 2024 Apr 15.
3

本文引用的文献

1
RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges.RNA 药物和小分子的 RNA 靶点:原理、进展与挑战。
Pharmacol Rev. 2020 Oct;72(4):862-898. doi: 10.1124/pr.120.019554.
2
Clinical Course in a Patient With Spinal Muscular Atrophy Type 0 Treated With Nusinersen and Onasemnogene Abeparvovec.接受 nusinersen 和 onasemnogene abeparvovec 治疗的脊髓性肌萎缩症 0 型患者的临床病程。
J Child Neurol. 2020 Oct;35(11):717-723. doi: 10.1177/0883073820928784. Epub 2020 Jun 9.
3
New and emerging pharmacotherapy for duchenne muscular dystrophy: a focus on synthetic therapeutics.
Real-world evidence: Risdiplam in a patient with spinal muscular atrophy type I with a novel splicing mutation and one SMN2 copy.
真实世界证据:利司扑兰治疗 I 型脊髓性肌萎缩伴新型剪接突变和 1 个 SMN2 拷贝的患者。
Hum Mol Genet. 2024 Jun 21;33(13):1120-1130. doi: 10.1093/hmg/ddae052.
4
Co-Occurrence of Myotonic Dystrophy Type 1 and Limb-Girdle Muscular Dystrophy Type 2B: A Case Report.1型强直性肌营养不良与2B型肢带型肌营养不良共病:一例报告
Mol Syndromol. 2024 Feb;15(1):58-62. doi: 10.1159/000533219. Epub 2023 Aug 22.
新型和新兴的杜氏肌营养不良症药物治疗:聚焦于合成疗法。
Expert Opin Pharmacother. 2020 May;21(7):841-851. doi: 10.1080/14656566.2020.1732350. Epub 2020 Mar 5.
4
The promise and challenge of therapeutic genome editing.治疗性基因组编辑的前景与挑战。
Nature. 2020 Feb;578(7794):229-236. doi: 10.1038/s41586-020-1978-5. Epub 2020 Feb 12.
5
New developments in gene editing for Duchenne muscular dystrophy.杜氏肌营养不良症基因编辑的新进展。
Nat Rev Cardiol. 2020 Apr;17(4):200-201. doi: 10.1038/s41569-020-0350-7.
6
Duchenne muscular dystrophy.杜兴氏肌肉营养不良症
BMJ. 2020 Jan 23;368:l7012. doi: 10.1136/bmj.l7012.
7
Current and future treatments of spinal muscular atrophy.
Dev Med Child Neurol. 2020 Mar;62(3):267. doi: 10.1111/dmcn.14447. Epub 2019 Dec 26.
8
News Feature: Gene therapy successes point to better therapies.新闻特写:基因治疗的成功预示着更好疗法的出现。
Proc Natl Acad Sci U S A. 2019 Nov 26;116(48):23866-23870. doi: 10.1073/pnas.1918306116.
9
More is needed to complement the available therapies of spinal muscular atrophy.需要更多措施来补充现有的脊髓性肌萎缩症治疗方法。
Future Med Chem. 2019 Nov;11(22):2873-2876. doi: 10.4155/fmc-2019-0239. Epub 2019 Oct 31.
10
Onasemnogene Abeparvovec: First Global Approval.Onasemnogene Abeparvovec:全球首次获批。
Drugs. 2019 Jul;79(11):1255-1262. doi: 10.1007/s40265-019-01162-5.